Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Sanjay S. Patel, CFA, as Chief Financial Officer, effective July 15, 2019. Mr. Patel replaces Tamara A. Seymour, who has served as the companys Interim Chief Financial Officer since April 26, 2019.
Novo Holdings A/S (Novo Holdings) invests $72m in LanzaTech to support development of the companys sustainable fuels and chemicals platform
SillaJen, the licensor for French immunoncology specialist Transgene SA, has stopped enrolment into the Phase III Phocus trial after an Independent Data Review Comittee predicted the study endpoint won’t be met.
Pieris Pharmaceuticals, Inc. today announced that Maya R. Said, Sc.D., has joined the Companys Board of Directors.
Wellington Partners has closed its largest Life Sciences Fund ever. The VC specialist outperformed its intial target of raising €120m to €150m and closed at €210m.